Phathom Pharmaceuticals, Inc. Book value per Share

Book value per Share of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.


Highlights and Quick Summary

  • Book value per Share for the quarter ending June 29, 2021 was 3.61 (a -20.34% decrease compared to previous quarter)
  • Year-over-year quarterly Book value per Share decreased by -23.05%
  • Annual Book value per Share for 2020 was 5.85 (a -36.58% decrease from previous year)
  • Annual Book value per Share for 2019 was 9.22 (a -17692.37% decrease from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of Phathom Pharmaceuticals, Inc.

Most recent Book value per Shareof PHAT including historical data for past 10 years.

Interactive Chart of Book value per Share of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 3.61 4.53
2020 5.7 4.69 5.71 6.43 5.85
2019 20.05 -20.81 0.0 0.0 9.22
2018 0.0 0.0 -0.05

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.